Tian Hui, Sui Yuanda, Tian Suochen, Zou Xiuli, Xu Zhiping, He Huang, Wu Tiejun
Department of Critical Care Medicine, Liaocheng People's Hospital, Liaocheng, China.
Front Med (Lausanne). 2020 May 28;7:249. doi: 10.3389/fmed.2020.00249. eCollection 2020.
This paper reports the clinical characteristics, diagnosis, and treatment of the first critical COVID-19 patient in Liaocheng City, who was admitted to the intensive care unit isolation ward of Liaocheng People's Hospital on February 11, 2020. On admission, the patient had difficulty breathing, the oxygenation index was 135 mmHg, and the blood lactate was 5.6 mmol/L. After comprehensive treatment including high-flow nasal cannula oxygen therapy, plasma exchange, antiviral and anti-infection therapies, immune regulation, liquid volume management, glucocorticoid, enteral nutrition support, analgesia and sedation, blood glucose control, anticoagulation and thrombus prevention, and electrolyte balance maintenance, the patient was finally cured, and discharged. The purpose of this case report is to provide a reference for the clinical diagnosis and treatment of critical COVID-19 patients.
本文报道了聊城市首例危重型新型冠状病毒肺炎患者的临床特征、诊断及治疗情况。该患者于2020年2月11日入住聊城市人民医院重症监护室隔离病房。入院时,患者呼吸困难,氧合指数为135mmHg,血乳酸为5.6mmol/L。经过包括高流量鼻导管吸氧治疗、血浆置换、抗病毒及抗感染治疗、免疫调节、液体管理、糖皮质激素、肠内营养支持、镇痛镇静、血糖控制、抗凝及预防血栓形成以及维持电解质平衡等综合治疗后,患者最终治愈出院。本病例报告旨在为危重型新型冠状病毒肺炎患者的临床诊断及治疗提供参考。